121 related articles for article (PubMed ID: 12749003)
21. 1,4-Naphthoquinone is a potent inhibitor of human cancer cell growth and angiogenesis.
Kayashima T; Mori M; Yoshida H; Mizushina Y; Matsubara K
Cancer Lett; 2009 Jun; 278(1):34-40. PubMed ID: 19168278
[TBL] [Abstract][Full Text] [Related]
22. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
23. A novel polyacetylene significantly inhibits angiogenesis and promotes apoptosis in human endothelial cells through activation of the CDK inhibitors and caspase-7.
Wu LW; Chiang YM; Chuang HC; Lo CP; Yang KY; Wang SY; Shyur LF
Planta Med; 2007 Jun; 73(7):655-61. PubMed ID: 17559025
[TBL] [Abstract][Full Text] [Related]
24. Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity.
Honda T; Tajima H; Kaneko Y; Ban M; Inaba T; Takeno Y; Okamoto K; Aono H
Bioorg Med Chem Lett; 2008 May; 18(9):2939-43. PubMed ID: 18420406
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic constituents of Brachistus stramoniifolius.
Fang L; Chai HB; Castillo JJ; Soejarto DD; Farnsworth NR; Cordell GA; Pezzuto JM; Kinghorn AD
Phytother Res; 2003 May; 17(5):520-3. PubMed ID: 12748990
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic activity of a concentrated effective microorganism fermentation extract.
Chui CH; Gambari R; Lau FY; Hau DK; Wong RS; Cheng GY; Kok SH; Higa T; Ke B; Chan AS; Fong DW; Tang JC
Int J Mol Med; 2006 Nov; 18(5):975-9. PubMed ID: 17016630
[TBL] [Abstract][Full Text] [Related]
27. Isolation of an anti-tumour terpenoid from stem bark of Spondianthus preussii var. preussii Engl.
Abo KA; Kinghorn AD
Afr J Med Med Sci; 2003 Jun; 32(2):179-82. PubMed ID: 15032466
[TBL] [Abstract][Full Text] [Related]
28. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Okazaki T; Nishihara S; Arai K; Yamaguchi S; Shibuya M; Nakaike S; Tanaka M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):16-24. PubMed ID: 15064856
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
Mistry SJ; Bank A; Atweh GF
Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914
[TBL] [Abstract][Full Text] [Related]
30. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
31. Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells.
Liu S; Wu P; Ye D; Huang Y; Zhou X; Li Y; Cai L
Pharmacology; 2009; 84(1):17-23. PubMed ID: 19478549
[TBL] [Abstract][Full Text] [Related]
32. Anti-angiogenic and anti-tumor activities of isoflavonoids from the rhizomes of Belamcanda chinensis.
Jung SH; Lee YS; Lee S; Lim SS; Kim YS; Ohuchi K; Shin KH
Planta Med; 2003 Jul; 69(7):617-22. PubMed ID: 12898416
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic activity of Bupleurum longiradiatum on human umbilical venous endothelial cells.
You YJ; Lee IS; Kim Y; Bae KH; Ahn BZ
Arch Pharm Res; 2002 Oct; 25(5):640-2. PubMed ID: 12433197
[TBL] [Abstract][Full Text] [Related]
34. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
Chillemi F; Francescato P; Ragg E; Cattaneo MG; Pola S; Vicentini L
J Med Chem; 2003 Sep; 46(19):4165-72. PubMed ID: 12954068
[TBL] [Abstract][Full Text] [Related]
35. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
36. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
37. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Ng SS; Gütschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD
Cancer Res; 2003 Jun; 63(12):3189-94. PubMed ID: 12810647
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.
Watanabe J; Endo Y; Shimada N; Natsume T; Sasaki T; Kobayashi M
In Vivo; 2007; 21(2):297-304. PubMed ID: 17436580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]